

Hui Shao

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4353423/publications.pdf>

Version: 2024-02-01

46
papers

658
citations

623734

14
h-index

642732

23
g-index

48
all docs

48
docs citations

48
times ranked

910
citing authors

#	ARTICLE	IF	CITATIONS
1	Socioeconomic Factors Play a More Important Role than Clinical Needs in the Use of SGLT2 Inhibitors and GLP-1 Receptor Agonists in People With Type 2 Diabetes. <i>Diabetes Care</i> , 2022, 45, e32-e33.	8.6	3
2	Efficacy of iGlarLixi on 5-year risk of diabetes-related complications: A simulation study. <i>Journal of Diabetes and Its Complications</i> , 2022, 36, 108132.	2.3	2
3	A National Catalog of Mapped Short-Form Six-Dimension Utility Scores for Chronic Conditions in the United States From 2010 to 2015. <i>Value in Health</i> , 2022, , .	0.3	1
4	Selecting a target population for type 2 diabetes lifestyle prevention programs: A cost-effectiveness perspective. <i>Diabetic Medicine</i> , 2022, , e14847.	2.3	2
5	Potential Gains in Life Expectancy Associated With Achieving Treatment Goals in US Adults With Type 2 Diabetes. <i>JAMA Network Open</i> , 2022, 5, e227705.	5.9	15
6	Newer glucose-lowering drugs and risk of dementia: A meta-analysis of cardiovascular outcome trials. <i>Journal of the American Geriatrics Society</i> , 2022, 70, 2719-2722.	2.6	4
7	Projected Impact of the Medicare Part D Senior Savings Model on Diabetes-Related Health and Economic Outcomes Among Insulin Users Covered by Medicare. <i>Diabetes Care</i> , 2022, 45, 1814-1821.	8.6	4
8	Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM-CURE risk score. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 2203-2211.	4.4	6
9	Cost-Effectiveness of the New 2018 American College of Physicians Glycemic Control Guidance Statements Among US Adults With Type 2 Diabetes. <i>Value in Health</i> , 2021, 24, 227-235.	0.3	0
10	Trends in Total and Out-of-pocket Payments for Noninsulin Glucose-Lowering Drugs Among U.S. Adults With Large-Employer Private Health Insurance From 2005 to 2018. <i>Diabetes Care</i> , 2021, 44, 925-934.	8.6	7
11	Estimates of insulin needs and dispensation given wastage, alternative glycemic targets, and non-insulin therapies in US populations with type 2 diabetes mellitus: A microsimulation study. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107839.	2.3	4
12	Income, Relative Deprivation and the Self-Rated Health of Older People in Urban and Rural China. <i>Frontiers in Public Health</i> , 2021, 9, 658649.	2.7	18
13	A varied approach to left ventricular assist device follow-up improves cost-effectiveness. <i>Current Medical Research and Opinion</i> , 2021, 37, 1501-1505.	1.9	0
14	Comparing the downstream costs and healthcare utilization associated with the use of low-dose computed tomography (LDCT) in lung cancer screening in patients with and without Alzheimer's disease and related dementias (ADRD). <i>Current Medical Research and Opinion</i> , 2021, 37, 1731-1737.	1.9	1
15	The diminishing cost-effectiveness of the newer glucose-lowering drug classes in the United States: 2010-2018. <i>Current Medical Research and Opinion</i> , 2021, 37, 1-6.	1.9	0
16	Trends in Total and Out-of-pocket Payments for Insulin Among Privately Insured U.S. Adults With Diabetes From 2005 to 2018. <i>Diabetes Care</i> , 2021, , dc202529.	8.6	3
17	Comparing cardiovascular benefits between GLP-1 receptor agonists and SGLT2 inhibitors as an add-on to metformin among patients with type 2 diabetes: A retrospective cohort study. <i>Journal of Diabetes and Its Complications</i> , 2021, 35, 107972.	2.3	14
18	Association between frailty and life satisfaction among older people in Shandong, China: the differences in age and general self-efficacy. <i>Psychogeriatrics</i> , 2020, 20, 172-179.	1.2	14

#	ARTICLE	IF	CITATIONS
19	Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis. <i>BMC Medicine</i> , 2020, 18, 378.	5.5	13
20	Trajectories of Short Physical Performance Battery Are Strongly Associated with Future Major Mobility Disability: Results from the LIFE Study. <i>Journal of Clinical Medicine</i> , 2020, 9, 2332.	2.4	9
21	Factors Contributing to the Rising National Cost of Glucose-Lowering Medicines for Diabetes During 2005–2007 and 2015–2017. <i>Diabetes Care</i> , 2020, 43, 2396-2402.	8.6	37
22	Estimating costs of diabetes complications in people –years in the U.S. using panel data. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107735.	2.3	17
23	Impact of Quality Improvement (QI) Program on 5-Year Risk of Diabetes-Related Complications: A Simulation Study. <i>Diabetes Care</i> , 2020, 43, 2847-2852.	8.6	9
24	Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge. <i>Value in Health</i> , 2020, 23, 1163-1170.	0.3	32
25	Using the BRAVO Risk Engine to Predict Cardiovascular Outcomes in Clinical Trials With Sodium–Glucose Transporter 2 Inhibitors. <i>Diabetes Care</i> , 2020, 43, 1530-1536.	8.6	16
26	A Systematic Review of Cost-Effectiveness of Sodium-Glucose Cotransporter Inhibitors for Type 2 Diabetes. <i>Current Diabetes Reports</i> , 2020, 20, 12.	4.2	21
27	Does the Encounter Type Matter When Defining Diabetes Complications in Electronic Health Records?. <i>Medical Care</i> , 2020, 58, S53-S59.	2.4	2
28	Comment on Segar et al. Machine Learning to Predict the Risk of Incident Heart Failure Hospitalization Among Patients With Diabetes: The WATCH-DM Risk Score. <i>Diabetes Care</i> 2019;42:2298–2306. <i>Diabetes Care</i> , 2020, 43, e25-e25.	8.6	1
29	Serum uric acid as a risk factor of all-cause mortality and cardiovascular events among type 2 diabetes population: Meta-analysis of correlational evidence. <i>Journal of Diabetes and Its Complications</i> , 2019, 33, 107409.	2.3	25
30	Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis. <i>Diabetes Care</i> , 2019, 42, 2136-2142.	8.6	10
31	Addressing Regional Differences in Diabetes Progression: Global Calibration for Diabetes Simulation Model. <i>Value in Health</i> , 2019, 22, 1402-1409.	0.3	13
32	Cost Effectiveness of Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors, Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists, and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: A Systematic Review. <i>Pharmacoeconomics</i> , 2019, 37, 777-818.	3.3	30
33	Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. <i>Pharmacoeconomics</i> , 2019, 37, 921-929.	3.3	35
34	An exploratory spatial analysis of overweight and obesity among children and adolescents in Shandong, China. <i>BMJ Open</i> , 2019, 9, e028152.	1.9	11
35	9-OR: Cost Effectiveness of the New 2018 ACP Glycemic Control Guideline among U.S. Adults with Type 2 Diabetes. <i>Diabetes</i> , 2019, 68, .	0.6	1
36	Cost Sharing of Disease-Modifying Treatments (DMTs) as Policy Lever to Improve DMTs™ Access in Multiple Sclerosis. <i>Value in Health</i> , 2018, 21, 1083-1089.	0.3	18

#	ARTICLE	IF	CITATIONS
37	Long-term outcomes associated with triple-goal achievement in patients with type 2 diabetes mellitus (T2DM). <i>Diabetes Research and Clinical Practice</i> , 2018, 140, 45-54.	2.8	15
38	Concordance of Adherence Measurement Using Self-Reported Adherence Questionnaires and Medication Monitoring Devices: An Updated Review. <i>Pharmacoeconomics</i> , 2018, 36, 17-27.	3.3	51
39	Estimating benefit equity of government health subsidy in healthcare Services in Shandong Province, China: a cross-sectional study. <i>International Journal for Equity in Health</i> , 2018, 17, 61.	3.5	6
40	Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). <i>Pharmacoeconomics</i> , 2018, 36, 1125-1134.	3.3	61
41	Projecting Long-Term Diabetes Complications through a BRAVO-Based Mock Simulation for Promoting Diabetes Prevention Program (DPP). <i>Diabetes</i> , 2018, 67, 701-P.	0.6	1
42	Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus. <i>Current Medical Research and Opinion</i> , 2017, 33, 359-369.	1.9	29
43	The impact of a bundled policy intervention on improving the performance of rural healthcare in China. <i>International Journal for Equity in Health</i> , 2016, 15, 46.	3.5	10
44	Cost-effectiveness analysis of exenatide twice daily (BID) vs insulin glargine once daily (QD) as add-on therapy in Chinese patients with Type 2 diabetes mellitus inadequately controlled by oral therapies. <i>Journal of Medical Economics</i> , 2015, 18, 974-989.	2.1	13
45	Mapping and Analyzing Stakeholders in China's Essential Drug System by Using a Circular Model: Who We Should Deal with Next?. <i>Value in Health Regional Issues</i> , 2015, 6, 111-117.	1.2	2
46	Is hypoglycemia fear independently associated with health-related quality of life?. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 167.	2.4	45